The atopic dermatitis (AD) market is forecasted to grow from $5.3 billion in 2021 to $22.6 billion by 2031, with a compound annual growth rate (CAGR) of 15.1%, according to a new report.
North America as the current market leader, according to a press release from Allied Market Research, fueled by robust healthcare infrastructure and adoption of advanced therapies like biologics, while the Asia-Pacific region is expected to grow at the fastest rate due to increasing healthcare investments and other factors.
The report also emphasized the growing demand for both topical and systemic therapies, as well as the importance of personalized medicine. Key players profiled in the report include Bayer AG, Novartis, Pfizer, and Dermavant Sciences.
The analysis also included a section addressing the ongoing impact of the pandemic, noting initial disruptions in treatment access during COVID-19.
Source: Allied Market Research press release. December 9, 2024.